Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is a $1.09 billion market cap biotech company focused on solutions for infectious diseases. The company has a pipeline of drugs in Phase 2 trials for the treatment of Hepatitis C Virus (HCV) that show promise. For patients taking those drugs, Achillion expects the drugs to treat and cure HCV in about 4 to 6 weeks. If approved, Achillion’s drugs would be superior to Gilead’s blockbuster drugs, Harvoni and Sovaldi, which take 12 weeks to cure HCV. Achillion estimates HCV affects 3-5 million in the U.S. and 7 to 11 million people in the combined US, EU, and Japan. Total HCV sales reached approximately $15 billion in 2014 and Achillion forecasts sales to reach $20 billion in 2016.

Follow Achillion Pharmaceuticals Inc (NASDAQ:ACHN)
Trade (NASDAQ:ACHN) Now!

In May 2015, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) made a deal with Johnson & Johnson’s subsidiary, Janssen, in which Achillion would be eligible to receive up to $905 million in milestone payments and a mid-teens to low-twenties tiered royalty percentage on any drugs that use Achillion’s HCV assets (such as Odalasvir). Janssen is responsible for all development and commercialization costs over those drugs. On July 1 2015, Achillion also received $225 million in cash in exchange for giving Johnson & Johnson 18,367,346 shares at a price of $12.25. In October 2015, a unit of Janssen Pharmaceutical initiated a phase 2a clinical trial assessing the combination of Odalasvir, AL-335, and simeprevir in treatment naive HCV-1 patients. The study should be completed in August of 2016. In May 2016, the same unit initiated a Phase 2b trial assessing different combinations of the cocktail’s safety and efficacy for patients with certain types of HCV. The study should end in end in July 2017.

Although the Janssen deal provides Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) with substantial liquidity, Achillion shares have retracted because many investors were expecting a buyout of Achillion instead. Some investors also sold because there is no guarantee that Janssen will use Achillion’s HCV assets, as Janssen already has a nucleotide polymerase and protease inhibitor. Despite the weakness, hedge funds are long Achillion because Achillion’s HCV assets are in some ways superior to Janssen’s inhibitors (otherwise the deal wouldn’t have happened) and the HCV market is big enough for mid-teen royalties to drive Achillion stock. In addition, Achillion has a promising platform of preclinical complement factor D inhibitors that can treat complement-related diseases such as myasthenia gravis. Analysts have a $9.50 price target.

With this in mind, let’s take a look at how hedge funds and other institutional investors we track have been trading shares of Achillion Pharmaceuticals.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.